AstraZeneca misses estimates as higher R&D spending offsets oncology growth

AstraZeneca (NASDAQ:AZN) reported fourth-quarter and full-year 2025 results on Tuesday that failed to meet Wall Street’s expectations, as a surge in operating costs for its expanding drug pipeline dampened the impact of double-digit sales growth in its oncology division.

For the quarter ended December 31, 2025, the Cambridge-based pharmaceutical giant posted adjusted earnings of $1.06 per share, significantly missing the $2.18 per share average estimate from analysts surveyed by Zacks Investment Research.

Total revenue for the quarter reached $15.5 billion, a 4% increase from the prior year but slightly below the $15.78 billion forecast.

The company's net income for the period was $2.33 billion, or $0.75 per share.

The bottom-line pressure was largely attributed to a planned increase in core operating expenses—including a 24% R&D-to-revenue ratio—as the firm manages an unprecedented 16 positive Phase 3 readouts and targets 43 approvals across major global regions.

For the full year 2025, AstraZeneca reported a total profit of $10.23 billion on revenue of $58.74 billion, an 8% increase at constant exchange rates.

CEO Pascal Soriot emphasized the company's long-term trajectory, noting that AstraZeneca now boasts 16 "blockbuster" medicines.

Despite the quarterly miss, the company provided a constructive outlook for 2026, anticipating mid-to-high single-digit percentage growth in total revenue and low double-digit growth in core earnings per share.